The nation of Zimbabwe has turned down a major American healthcare agreement valued at $367m (272 million pounds) over five years due to the United States' insistence on confidential information.
This rejection was revealed after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative later stated that the United States was seeking biological samples for scientific study and profit but was unwilling to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged more talks to secure a agreement suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
Based on reports, Sixteen African countries have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that might result from that shared data," he stated.
"Effectively, our nation would supply the raw materials for medical research with no assurance that the final treatments would be accessible to our people should a future disease outbreak emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of one-on-one deals were upending frameworks previously established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is designed to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We encourage ongoing discussions with our American counterparts on how future co-operation might be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Response
A leading public health body expressed it recognised the government's concerns, but urged that negotiations should continue considering a large portion of the nation's HIV programmes depended on foreign aid.
"In cases where specific concerns arise, such as those involving information security or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," it added.
The situation highlights the ongoing challenges between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.